Soleno Therapeutics (SLNO) SVP granted 10,400 RSUs and 11,900 stock options

Rhea-AI Filing Summary

Soleno Therapeutics senior vice president of clinical development Michael F. Huang reported equity awards in the company’s stock. On January 21, 2026, he received 10,400 shares of Common Stock for no cash consideration, structured as restricted stock units that each convert into one share if service conditions are met. Following this award, he directly beneficially owned 46,405 shares of Common Stock, some of which are RSUs subject to their own vesting terms.

On the same date, he was also granted an employee stock option covering 11,900 shares of Common Stock at an exercise price of $43.65 per share, expiring on January 21, 2036. One forty‑eighth of the option vests on February 1, 2026 and on each monthly anniversary thereafter, provided he continues as a service provider, while the 10,400 RSUs are scheduled to vest in full on December 15, 2027 under the same continued‑service condition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huang Michael F.

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP of Clinical Development

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		A		10,400(1)	A	$0	46,405(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$43.65	01/21/2026		A		11,900		(3)	01/21/2036	Common Stock	11,900	$0	11,900	D

Explanation of Responses:

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.

2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

	/s/ Anish Bhatnagar, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SLNO executive Michael F. Huang report?

Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics (SLNO), reported receiving 10,400 restricted stock units of Common Stock and an option for 11,900 shares on January 21, 2026.

How many Soleno Therapeutics shares does Michael F. Huang beneficially own after this Form 4?

After the reported grant, Michael F. Huang beneficially owned 46,405 shares of Soleno Therapeutics Common Stock, including shares represented by RSUs, held directly.

What are the vesting terms for Michael F. Huang’s 10,400 RSUs in SLNO?

The 10,400 RSUs granted to Michael F. Huang are scheduled to vest 100% on December 15, 2027, if he continues to be a service provider under the company’s 2014 Equity Incentive Plan through that date.

What are the key terms of Michael F. Huang’s 11,900-share stock option in Soleno Therapeutics?

The employee stock option covers 11,900 shares of Common Stock at an exercise price of $43.65 per share, expiring on January 21, 2036. 1/48th of the shares vest on February 1, 2026 and on each one‑month anniversary thereafter, subject to continued service.

Did Michael F. Huang pay cash for the SLNO shares and options reported?

The Form 4 shows a price of $0 for both the 10,400-share RSU grant and the 11,900-share option grant, indicating these were equity awards rather than open‑market purchases.

Are Michael F. Huang’s Soleno equity awards subject to continued service conditions?

Yes. Both the RSUs and the stock option are subject to continued service as a “Service Provider” under Soleno’s 2014 Equity Incentive Plan through the applicable vesting dates.